Literature DB >> 17728711

Surgery insight: surgical management of pancreatic cancer.

Christoph W Michalski1, Jürgen Weitz, Markus W Büchler.   

Abstract

Pancreatic ductal adenocarcinoma is a common malignancy of the gastrointestinal tract. The number of new cases diagnosed and the number of deaths each year are almost identical, demonstrating the particularly dismal prognosis for patients affected by this disease. Despite recent advances in the field of medical and radiation oncology, and the introduction of neoadjuvant and adjuvant regimens, surgery remains the single most important modality for the treatment of pancreatic ductal adenocarcinoma. Surgery for pancreatic cancer is widely viewed as a complex procedure associated with considerable perioperative morbidity and mortality. Many aspects of surgery for pancreatic cancer, such as the extent of resection, the value of vascular resection, the use of laparoscopy, and the importance of treatment at high-volume centers, are currently under debate. This Review describes the current status of surgical treatment for pancreatic ductal adenocarcinoma, and highlights the new developments in this field.

Entities:  

Mesh:

Year:  2007        PMID: 17728711     DOI: 10.1038/ncponc0925

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  24 in total

1.  Redefining mortality after pancreatic cancer resection.

Authors:  James Edward Carroll; Jillian K Smith; Jessica P Simons; Melissa M Murphy; Sing Chau Ng; Shimul A Shah; Zheng Zhou; Jennifer F Tseng
Journal:  J Gastrointest Surg       Date:  2010-09-16       Impact factor: 3.452

2.  [Pylorus-preserving pancreatic head resection. Video article].

Authors:  C J Bruns; F C Popp
Journal:  Chirurg       Date:  2016-04       Impact factor: 0.955

3.  Total meso-pancreatoduodenum excision with pancreaticoduodenectomy in lower biliary tract cancer.

Authors:  Yasunari Kawabata; Hikota Hayashi; Noriyoshi Ishikawa; Yoshitsugu Tajima
Journal:  Langenbecks Arch Surg       Date:  2016-04-21       Impact factor: 3.445

Review 4.  Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas.

Authors:  Daniel Åkerberg; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

5.  Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity.

Authors:  Ian R Munhenzva; Connor W Barth; Martha Sibrian-Vazquez; Lei G Wang; Jorge O Escobedo; Summer L Gibbs; Robert M Strongin
Journal:  Methods       Date:  2019-06-08       Impact factor: 3.608

6.  Negative methylation status of vimentin predicts improved prognosis in pancreatic carcinoma.

Authors:  Yi-Feng Zhou; Wei Xu; Xia Wang; Jin-Shan Sun; Jing-Jing Xiang; Zhao-Shen Li; Xiao-Feng Zhang
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

7.  How Does Outcomes Research Help Advance Our Knowledge of Patient Outcomes in Hepatopancreaticobiliary Surgery?

Authors:  Donna Marie L Alvino; David C Chang; Zhi Ven Fong
Journal:  J Gastrointest Surg       Date:  2016-02-09       Impact factor: 3.452

8.  Integrated in silico and 3D in vitro model of macrophage migration in response to physical and chemical factors in the tumor microenvironment.

Authors:  Sharon Wei Ling Lee; R J Seager; Felix Litvak; Fabian Spill; Je Lin Sieow; Penny Hweixian Leong; Dillip Kumar; Alrina Shin Min Tan; Siew Cheng Wong; Giulia Adriani; Muhammad Hamid Zaman; And Roger D Kamm
Journal:  Integr Biol (Camb)       Date:  2020-04-20       Impact factor: 2.192

9.  The role of surgery for pancreatic cancer: a 12-year review of patient outcome.

Authors:  S A Badger; J L Brant; C Jones; J McClements; M B Loughrey; M A Taylor; T Diamond; L D McKie
Journal:  Ulster Med J       Date:  2010-05

10.  Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro.

Authors:  Su-Gang Shen; Dong Zhang; Heng-Tong Hu; Jun-Hui Li; Zheng Wang; Qing-Yong Ma
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.